

Company

FIMECS, Inc.

~ Drugging Undruggable Targets~

Presenter

Yusuke Kohno



FIMECS is a drug discovery biotech developing a new class of targeted protein degradation therapeutics for disease relevant “undruggable” targets.

- Proprietary E3 ligase driven degrader drug discovery platform “RaPPIDS™”
- Pre-clinical stage assets targeting **pseudokinase** in oncology area
- Seeking license, co-development, and discovery collaboration partners
- Planning series A fund raising early 2019

